WO2019093497A8 - Ａｄａｍｔｓ５に対するアプタマー及びその使用 - Google Patents

Ａｄａｍｔｓ５に対するアプタマー及びその使用 Download PDF

Info

Publication number
WO2019093497A8
WO2019093497A8 PCT/JP2018/041746 JP2018041746W WO2019093497A8 WO 2019093497 A8 WO2019093497 A8 WO 2019093497A8 JP 2018041746 W JP2018041746 W JP 2018041746W WO 2019093497 A8 WO2019093497 A8 WO 2019093497A8
Authority
WO
WIPO (PCT)
Prior art keywords
aptamer
adamts5
ggggccucc
formula
ggacyaaacc
Prior art date
Application number
PCT/JP2018/041746
Other languages
English (en)
French (fr)
Other versions
WO2019093497A1 (ja
Inventor
一晃 青木
Original Assignee
株式会社リボミック
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社リボミック filed Critical 株式会社リボミック
Priority to CN201880072486.6A priority Critical patent/CN111542607A/zh
Priority to CA3081823A priority patent/CA3081823A1/en
Priority to KR1020207016137A priority patent/KR20200079534A/ko
Priority to US16/761,880 priority patent/US11473089B2/en
Priority to JP2019552413A priority patent/JPWO2019093497A1/ja
Priority to AU2018363996A priority patent/AU2018363996A1/en
Priority to EP18875651.4A priority patent/EP3708666A4/en
Priority to SG11202004154SA priority patent/SG11202004154SA/en
Priority to IL274435A priority patent/IL274435B1/en
Publication of WO2019093497A1 publication Critical patent/WO2019093497A1/ja
Publication of WO2019093497A8 publication Critical patent/WO2019093497A8/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本発明は、A disintegrin and metalloproteinase with thrombospondin motifs-5(ADAMTS5)に結合するアプタマーであって、以下の式（１）または式（２） （１）ＧＧＧＧＣＣＵＣＣ－Ｎ１－ＧＧＡＣＹＡＡＡＣＣ （２）ＧＧＧＧＣＣＵＣＣ－Ｎ１－ＧＧＡＣＷＹＡＡＡＣＣ （式中、Ｎ１は、３～２４個の長さの塩基であり、ＹはＣまたはＵを表し、ＷはＡまたはＵを表す）で表される配列（ただし、ウラシルはチミンであってもよい）を含む、アプタマーを提供する。
PCT/JP2018/041746 2017-11-09 2018-11-09 Ａｄａｍｔｓ５に対するアプタマー及びその使用 WO2019093497A1 (ja)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CN201880072486.6A CN111542607A (zh) 2017-11-09 2018-11-09 针对adamts5的适配体及其应用
CA3081823A CA3081823A1 (en) 2017-11-09 2018-11-09 Aptamer for adamts5 and use for aptamer for adamts5
KR1020207016137A KR20200079534A (ko) 2017-11-09 2018-11-09 Adamts5에 대한 앱타머, 및 adamts5에 대한 앱타머의 용도
US16/761,880 US11473089B2 (en) 2017-11-09 2018-11-09 Aptamer for ADAMTS5 and use for aptamer for ADAMTS5
JP2019552413A JPWO2019093497A1 (ja) 2017-11-09 2018-11-09 Ａｄａｍｔｓ５に対するアプタマー及びその使用
AU2018363996A AU2018363996A1 (en) 2017-11-09 2018-11-09 Aptamer for ADAMTS5, and use for aptamer for ADAMTS5
EP18875651.4A EP3708666A4 (en) 2017-11-09 2018-11-09 APTAMER FOR ADAMTS5 AND USE FOR APTAMER FOR ADAMTS5
SG11202004154SA SG11202004154SA (en) 2017-11-09 2018-11-09 Aptamer for adamts5 and use for aptamer for adamts5
IL274435A IL274435B1 (en) 2017-11-09 2018-11-09 Aptamer for ADAMTS5, and use of aptamer for ADAMTS5

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017216280 2017-11-09
JP2017-216280 2017-11-09

Publications (2)

Publication Number Publication Date
WO2019093497A1 WO2019093497A1 (ja) 2019-05-16
WO2019093497A8 true WO2019093497A8 (ja) 2020-07-02

Family

ID=66437904

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2018/041746 WO2019093497A1 (ja) 2017-11-09 2018-11-09 Ａｄａｍｔｓ５に対するアプタマー及びその使用

Country Status (10)

Country Link
US (1) US11473089B2 (ja)
EP (1) EP3708666A4 (ja)
JP (2) JPWO2019093497A1 (ja)
KR (1) KR20200079534A (ja)
CN (1) CN111542607A (ja)
AU (1) AU2018363996A1 (ja)
CA (1) CA3081823A1 (ja)
IL (1) IL274435B1 (ja)
SG (1) SG11202004154SA (ja)
WO (1) WO2019093497A1 (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024054922A1 (en) * 2022-09-07 2024-03-14 Synoa Therapeutics, Llc Methods and compositions comprising novel bispecific antibodies

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2763958B2 (ja) 1990-06-11 1998-06-11 ネクスター ファーマスーティカルズ，インコーポレイテッド 核酸リガンド
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
WO1994008050A1 (en) 1992-09-29 1994-04-14 Nexagen, Inc. Nucleic acid ligands and methods for producing the same
JPH09502354A (ja) 1993-09-08 1997-03-11 ネクスター ファーマスーティカルズ，インコーポレイテッド 核酸リガンドと、同リガンドを製造するための改良された方法
KR20080036595A (ko) 2005-07-05 2008-04-28 가부시키가이샤 리보믹 면역글로불린 ｇ에 결합하는 핵산과 그 이용법
TWI532842B (zh) 2009-06-11 2016-05-11 力博美科股份有限公司 針對凝乳酶之適體及其用途
MX2012000055A (es) * 2009-07-02 2012-01-27 Glaxo Group Ltd Polipeptidos y metodo de tratamiento.
WO2015163458A1 (ja) * 2014-04-24 2015-10-29 株式会社リボミック オートタキシンに結合しオートタキシンの生理活性を阻害するアプタマー及びその利用
WO2016103042A1 (en) * 2014-12-25 2016-06-30 Guangzhou Ribobio Co., Ltd. Compositions and methods for inhibiting expression of adamts-5 and adam17
JP2017216280A (ja) 2016-05-30 2017-12-07 豊田合成株式会社 Ｉｉｉ 族窒化物半導体発光素子とその製造方法

Also Published As

Publication number Publication date
CA3081823A1 (en) 2019-05-16
JPWO2019093497A1 (ja) 2021-01-21
US20210246451A1 (en) 2021-08-12
US11473089B2 (en) 2022-10-18
EP3708666A1 (en) 2020-09-16
WO2019093497A1 (ja) 2019-05-16
EP3708666A4 (en) 2021-07-21
IL274435A (en) 2020-06-30
IL274435B1 (en) 2024-03-01
JP2023099157A (ja) 2023-07-11
SG11202004154SA (en) 2020-06-29
KR20200079534A (ko) 2020-07-03
AU2018363996A1 (en) 2020-05-28
CN111542607A (zh) 2020-08-14

Similar Documents

Publication Publication Date Title
EP4257613A3 (en) Bispecific checkpoint inhibitor antibodies
PH12017502090A1 (en) Heterocyclic amides as kinase inhibitors
EP4335874A3 (en) Anti-hla-g antibodies and use thereof
PH12016500676A1 (en) Pyrimidine fgfr4 inhibitors
MY175896A (en) Anti-complement factor c1q antibodies and uses thereof
MX2018008815A (es) Inhibidores de tirosina quinasa de bruton.
ATE485359T1 (de) Verwendung von grenzflächenaktiven, nicht- enzymatischen proteinen für die textilwäsche
BR112015016526A2 (pt) misturas de corantes com dispersão rápida e alta umidade
EA201992147A1 (ru) Ингибиторы тирозинкиназы брутона
MX2020010951A (es) Anticuerpos anti-hla-g y utilizacion de los mismos.
MX2020001793A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.
CR20140128A (es) Inhibidores de la enzima activadora de nedd 8
NZ712339A (en) Extensible fixing device
MX2019010643A (es) Formas y composiciones de un inhibidor de proteina cinasa 2 activada por la proteina cinasa activada por mitogeno (mk2).
PH12018502233A1 (en) ErbB INHIBITORS AND USES THEREOF
MX2015013365A (es) Derivados de urea y su uso como inhibidores de proteina de union de acidos grasos (puag).
MX2020003507A (es) Compuestos pirimidinicos inhibidores de (tbk)/(ikk) epsilon y usos de los mismos.
CL2022001452A1 (es) Inhibidores de masp-2 y métodos de uso.
WO2019093497A8 (ja) Ａｄａｍｔｓ５に対するアプタマー及びその使用
MY197202A (en) A liquid formulation of anti-tnf alpha antibody
EA201690434A1 (ru) Маркирующие соединения и их применение в анализах
MX2016009402A (es) Premezcla de abrillantador fluorescente.
CL2020001705A1 (es) Composición acuosa que comprende ácido 2-(dimetil-1h-pirazol-1-il) succínico y amoníaco.
AU2018203040A1 (en) Combined fixing tool
MX2015013374A (es) Derivados de urea y su uso como inhibidores de proteina de uniuon a acidos grasos (puag).

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18875651

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2019552413

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 3081823

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018363996

Country of ref document: AU

Date of ref document: 20181109

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20207016137

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2018875651

Country of ref document: EP

Effective date: 20200609